Peter Hillmen,Neal S. Young,Jörg Schubert,Robert A. Brodsky,Gèrard Socié,Petra Muus,Alexander Röth,Jeff Szer,Modupe Elebute,Ryotaro Nakamura,Paul Browne,Antonio M. Risitano,Anita Hill,Hubert Schrezenmeier,Chieh‐Lin Fu,Jarosław P. Maciejewski,Scott A. Rollins,Christopher F. Mojcik,Russell P. Rother,Lucio Luzzatto
We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH).